Future Science Group
Browse
Supplementary materials (8).docx (86.5 kB)

Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers - Supplementary materials

Download (86.5 kB)
figure
posted on 2022-08-22, 08:56 authored by Kangho Suh, Josh J Carlson, Fang Xia, Todd Williamson, Sean D Sullivan

  

eFigure 1. One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in colorectal cancer


eFigure 2. One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in soft tissue sarcoma


eTable 1. Sensitivity analysis fitting an exponential curve through the median points for progression-free and overall survival for entrectinib 

Funding

Bayer US LLC, (Grant / Award Number:)

History

Usage metrics

    Journal of Comparative Effectiveness Research

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC